Collegium Pharmaceutical Inc (COLL)vsViatris Inc (VTRS)
COLL
Collegium Pharmaceutical Inc
$29.47
+1.24%
HEALTHCARE · Cap: $1.15B
VTRS
Viatris Inc
$16.43
+0.86%
HEALTHCARE · Cap: $20.45B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 1729% more annual revenue ($14.56B vs $796.33M). COLL leads profitability with a 9.4% profit margin vs -2.0%. COLL earns a higher WallStSmart Score of 50/100 (C-).
COLL
Buy50
out of 100
Grade: C-
VTRS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+88.1%
Fair Value
$378.01
Current Price
$29.47
$348.54 discount
Intrinsic value data unavailable for VTRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 27 in profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
Earnings declined 46.6%
Distress zone — elevated risk
Elevated debt levels
ROE of -2.0% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : COLL
The strongest argument for COLL centers on Return on Equity, P/E Ratio.
Bull Case : VTRS
The strongest argument for VTRS centers on Price/Book. PEG of 1.12 suggests the stock is reasonably priced for its growth.
Bear Case : COLL
The primary concerns for COLL are Market Cap, EPS Growth, Altman Z-Score. Debt-to-equity of 2.59 is elevated, increasing financial risk.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
COLL profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.90 — expect wider price swings.
COLL is growing revenue faster at 8.9% — sustainability is the question.
VTRS generates stronger free cash flow (348M), providing more financial flexibility.
Bottom Line
COLL scores higher overall (50/100 vs 48/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Collegium Pharmaceutical Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?